Reported 8 months ago
Grail, a U.S. cancer diagnostic test maker spun off from Illumina, is focusing on its Galleri cancer-detection test to drive growth through partnerships with health systems, employers, and insurance companies. The blood test can detect multiple cancer types early and targets 80% of unscreened cancers, aiming for global accessibility pending regulatory approvals. Grail plans to submit for FDA approval in 2026, with over 100 commercial partnerships already established. Despite regulatory scrutiny on cancer death prevention evidence, Grail seeks to expand its market post-EU antitrust issues with Illumina, which led to a fine and Grail's divestment as an independent company with Illumina as a minority stakeholder.
Source: YAHOO